Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Variant||ETV6 - ROS1|
|Protein Effect||gain of function - predicted|
|Gene Variant Descriptions||ETV6-ROS1 results from the fusion of ETV6 and ROS1, and leads to constitutive ROS1 activation in cultured cells (PMID: 26939704) and therefore, is predicted to confer a gain of function.|
|Associated Drug Resistance|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ETV6 - ROS1||Advanced Solid Tumor||sensitive||Entrectinib||Preclinical - Cell line xenograft||Actionable||In a preclinical study, transformed cells expressing ETV6-ROS1 were sensitive to Rozlytrek (entrectinib), resulting in inhibition of cell proliferation in culture and decreased tumor growth in xenograft models (PMID: 26939704).||26939704|